Equillium Inc Quick Ratio (EQ) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Equillium Inc   (NASDAQ: EQ)

Equillium Inc 's Quick Ratio

EQ's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 18.92 above Equillium Inc average.

Within Major Pharmaceutical Preparations industry 24 other companies have achieved higher Quick Ratio than Equillium Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 151, from total ranking in the second quarter 2026 at 166.

Explain Quick Ratio?
How much Cash & cash equivalents EQ´s has?
What are EQ´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/EQ/financial-strength
https://api.csimarket.com/api/v1/companies/EQ/fundamentals
https://api.csimarket.com/api/v1/companies/EQ/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
EQ Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change -0.11 %
Y / Y Cash & cash equivalent Change 61 %
Quick Ratio MRQ 18.92
EQ's Total Ranking # 151
Seq. Current Liabilities Change 13.76 %
Seq. Cash & cash equivalent Change -6.72 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 25
Healthcare Sector # 41
Overall Market # 151


Quick Ratio Statistics
High Average Low
32.5 6.88 0.01
(Dec 31 2018)   (Sep. 30, 2007)




Financial Statements
Equillium Inc 's Current Liabilities $ 3 Millions Visit EQ's Balance sheet
Equillium Inc 's Cash & cash equivalent $ 53 Millions Visit EQ's Balance sheet
Source of EQ's Sales Visit EQ's Sales by Geography


Cumulative Equillium Inc 's Quick Ratio

EQ's Quick Ratio for the trailling 12 Months

EQ Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -50.86 %
Y / Y Cash & cash equivalent TTM Growth 147.37 %
Quick Ratio TTM 18.76
Total Ranking TTM # 3095
Seq. Current Liabilities TTM Growth -0.03 %
Seq. Cash & cash equivalent TTM Growth 11.11 %

Quick ratio ranking by company, industry and sector >> Back to EQ Financial Strength Comparisons >> Go to Compare EQ Quick Ratio to its Competitors

  News about Equillium Inc Quick Ratio

Equillium Inc. Balancing Progress in Immunotherapy Research with Competitive Market Challenges,

: Equillium Inc. a clinical-stage biotechnology firm focused on immunobiology for severe autoimmune and inflammatory disorders, has made notable strides recently. Notably, a poster was presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer, showcasing their innovative research findings. Despite positive developments on the research front, Equillium faced challenges in market share and revenue growth compared to its competitors in the same sector. This article offers an in-depth analysis of Equillium s current position within the biotech landscape, focusing on research presentations, financial performance, and competitive dynamics in the field of immunotherapy.Equillium Inc. (Nasdaq: EQ) has emerged as a promising player in the biopharmaceutical arena, demonstrating a commitment to leveraging immunobiology to address critical healthcare needs. The presentation of new data at the Society for Immunotherapy of Cancer’s annual meeting underscored Equillium s focus on innovative therapeutics aimed at treating severe autoimmune and inflammatory conditions. However, in conjunction with these scientific advancements, financial metrics reveal a sobering competitive landscape.

On the trailing twelve months basis EQ Cash & cash equivalent soared by 61 % in Q3 2026 year on year, while Current Liabilities increased to $3 millions, this led to increase in in Equillium Inc 's Quick Ratio to 18.76, above EQ average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 411 other companies have achieved higher Quick Ratio than Equillium Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2026 from 2605 to 3095.

Explain Quick Ratio?
How much Cash & cash equivalents EQ´s has?
What are EQ´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 412
Healthcare Sector # 821
Within the Market # 3095


trailing twelve months Quick Ratio Statistics
High Average Low
18.95 5.95 0.02
(Sep 30 2019)   (Sep. 30, 2007)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Rallybio Corporation  51.94 $ 90.693  Millions$ 1.746  Millions
Enliven Therapeutics Inc   45.41 $ 884.351  Millions$ 19.473  Millions
Vyne Therapeutics Inc   41.29 $ 268.860  Millions$ 6.511  Millions
Bicara Therapeutics Inc   40.75 $ 442.346  Millions$ 10.856  Millions
Tango Therapeutics Inc   38.85 $ 977.503  Millions$ 25.164  Millions
Trevi Therapeutics Inc   38.05 $ 299.408  Millions$ 7.869  Millions
Fulcrum Therapeutics Inc   35.70 $ 306.545  Millions$ 8.587  Millions
Boundless Bio Inc   33.60 $ 62.894  Millions$ 1.872  Millions
Avalyn Pharma Inc   32.64 $ 422.814  Millions$ 12.955  Millions
Immix Biopharma Inc   30.89 $ 336.303  Millions$ 10.889  Millions
Minerva Neurosciences Inc   30.46 $ 76.945  Millions$ 2.526  Millions
Contineum Therapeutics Inc   30.45 $ 244.484  Millions$ 8.028  Millions
Pasithea Therapeutics Corp   29.91 $ 82.419  Millions$ 2.756  Millions
Latigo Biotherapeutics, Inc.  28.73 $ 401.241  Millions$ 13.964  Millions
Amylyx Pharmaceuticals Inc   26.44 $ 768.132  Millions$ 29.048  Millions
Climb Bio Inc   25.98 $ 205.423  Millions$ 7.906  Millions
Prothena Corporation Public Limited Company  23.73 $ 271.368  Millions$ 11.434  Millions
Silo Pharma Inc  22.91 $ 8.051  Millions$ 0.351  Millions
Innoviva Inc   22.67 $ 1,134.297  Millions$ 50.030  Millions
Silence Therapeutics Plc  22.00 $ 247.659  Millions$ 11.259  Millions
Kailera Therapeutics Inc   21.40 $ 901.454  Millions$ 42.116  Millions
Cryoport inc   20.47 $ 653.343  Millions$ 31.911  Millions
Roivant Sciences Ltd   20.30 $ 5,683.045  Millions$ 279.911  Millions
Disc Medicine Inc   19.87 $ 682.816  Millions$ 34.360  Millions
Relmada Therapeutics Inc  19.30 $ 202.123  Millions$ 10.474  Millions
Mbx Biosciences Inc   19.14 $ 481.594  Millions$ 25.167  Millions
Telomir Pharmaceuticals Inc   19.07 $ 4.516  Millions$ 0.237  Millions
Equillium Inc   18.92 $ 53.322  Millions$ 2.819  Millions
Onkure Therapeutics Inc   18.58 $ 163.305  Millions$ 8.789  Millions
Benitec Biopharma Inc   18.38 $ 176.368  Millions$ 9.594  Millions

Date modified: 2026-11-13T21:16:03+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.